Qualigen Therapeutics, Inc. announced that it has entered into a Securities Purchase Agreement with returning investor, Alpha Capital Anstalt to issue an 8% Convertible Debenture in the principal amount of $550,000 and to issue a 5-year common stock purchase warrant to purchase 900,016 shares of common stock of the company at an exercise price of $0.26 per share for the gross proceeds of $550,000 on February 26, 2024. The Debenture would have a maturity date of December 31, 2024 and would be convertible, at any time, and from time to time, at investor?s option, into shares of common stock of the Company, at $0.6111 per share, subject to adjustment as described in the Debenture. The Debenture would accrue interest on its outstanding principal balance at the rate of 8% per annum, which would be payable at maturity.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.296 USD | +1.89% | +0.24% | -46.18% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.18% | 1.83M | |
+2.11% | 42.75B | |
+47.64% | 41.61B | |
+12.48% | 41.34B | |
-12.36% | 26.59B | |
+8.72% | 25.49B | |
-23.35% | 18.12B | |
+30.90% | 12.24B | |
-1.77% | 11.76B | |
+8.86% | 11B |
- Stock Market
- Equities
- QLGN Stock
- News Qualigen Therapeutics, Inc.
- Qualigen Therapeutics, Inc. announced that it expects to receive $0.55 million in funding from Alpha Capital Anstalt